News
MorphoSys: Partner erhält Medikamenten-Zulassung in Kanada
Der MorphoSys-Lizenzpartner Janssen hat in Kanada die Zulassung zur Behandlung erwachsener Patienten mit moderater bis schwerer Form von Schuppenflechte mit dem Medikament Tremfya erhalten. Das....
Why Nektar Therapeutics Shares Delivered a Stupendous 124% in November
After the company updated the timeline for filing its pain-relieving drug for approval from the Food and Drug Administration, and presented early-stage study results for its solid-tumor cancer....
Here's How Acadia Pharmaceuticals Crushed It in 2017
About 1 million patients in the U.S. suffer from Parkinson's disease. Unfortunately, nearly 40% of them will experience hallucinations and delusions in their daily life, which is a disease state....
The FDA Ushers In a New Era in Cancer Treatment
On Thursday, Foundation Medicine (NASDAQ: FMI) won a green light for its comprehensive DNA test, FoundationOne CDx. The approval clears the way for healthcare providers to quickly determine what....
This Marijuana Stock Is Poised for a Breakout Year in 2018 -- Here's What You'll Want to Know About It
Admittedly, 2017 so far has kind of been a ho-hum year for former high-flying marijuana stock GW Pharmaceuticals (NASDAQ: GWPH). For the most part, investors have just been waiting for the next....
Are Viruses a Problem for CAR-T Drugmakers?
Chimeric antigen receptor T-cell therapy (CAR-T) could change how doctors treat cancer patients; however, creating these drugs is complicated and a flurry of research and commercialization....
Here's How Alnylam Pharmaceuticals, Inc. Crushed It in 2017
After a horrible 2016 following the loss of its lead drug candidate, Alnylam Pharmaceuticals (NASDAQ: ALNY) has had a pretty stellar year, up 238% so far.Much of that increase has come in the last....
3 Growth Stocks for the Long Term
What investor doesn't like growth? If a stock generates enough growth, dividends and valuation become relatively insignificant. Growth is king.We asked three Motley Fool investors which growth....
Evotec: Schnäppchen oder fallendes Messer?
Evotec ist in diesen Tagen wieder in aller Munde. Der Aktienkurs kommt nicht auf die Beine und nach dem Ausverkauf der letzten Wochen um zeitweise bis zu 46 Prozent auf 12 EUR, wittern viele....
Can Teladoc Stock Keep Going After Last Week's 24% Pop?
One of last week's biggest winners makes house calls. Teladoc (NYSE: TDOC) soared 24.1% last week, making it the second best performer on the New York Stock Exchange. Teladoc moved higher after....
The Federal Government Just Broke Its Medical-Marijuana Promise
Few if any industries are growing at a quicker and more consistent pace in the U.S. than marijuana. A report released earlier this year by Marijuana Business Daily entitled "Marijuana Business....
Why Marijuana Stock GW Pharmaceuticals Skyrocketed 11% Today
After the company released updated clinical trial data showing efficacy of its marijuana drug as a monotherapy and improvement from baseline over long-term use, shares of GW....
5 Lesser-Known Rule Breakers: Where We Stand at the 2-Year Mark
On this week's Rule Breaker Investing podcast, Motley Fool co-founder David Gardner reviews the performance of a set of his stock picks made up of companies most folks won't have heard of.Based on....
3 Biotech Stocks to Be Thankful for This Year
Anyone who has been holding onto shares of Loxo Oncology Inc. (NASDAQ: LOXO), Nektar Therapeutics (NASDAQ: NKTR), or Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) will have plenty to say when it's....
3 Biotech Stocks That Soared: Are They Buys?
Some of the biggest moves week in and week out come from biotech stocks. Whether it's a financial surprise, a positive clinical-trial update, regulatory approval, or even just rumors of....
What’s Next for Nektar Therapeutics?
Nektar Therapeutics (NASDAQ: NKTR) has a lot on its plate. The company's advancing its lead drug candidate, NKTR-181, to the FDA for use in chronic pain and its pipeline crisscrosses....
Is Loxo Oncology's Deal With Bayer Bad News?
After reporting that global biopharma giant Bayer AG (NASDAQOTH: BAYRY) has inked a licensing deal for its most advanced clinical-stage drug, shares in Loxo Oncology (NASDAQ: LOXO) tumbled. Is....
The 4 Largest Pure-Play Marijuana Stocks
Marijuana hasn't come by the nickname "the green rush" by accident. If we take a closer look at the performance of marijuana stocks, most have had investors seeing a lot of green over the trailing....
A Big Hedge Fund Is Behind Mednax Soaring 12.7% Today
Shares of Mednax (NYSE: MD) were up 12.7% at 3:30 p.m. EST Thursday after Paul Singer's Elliott Management revealed a 7% stake in the company and agreed to speak to management about ways to boost....
Genomic Health, Inc. Turns a Profit (With an Asterisk)
Genomic Health (NASDAQ: GHDX) recorded a $1.1 million profit during the third quarter, something it's been shooting for as it's improved its bottom line for each of the last nine consecutive....
5 Supernova Stocks That Have Flown Under the Radar: NuVasive
Last week on the Rule Breaker Investing podcast, Motley Fool co-founder David Gardner reviewed the performance of two sets of his buy-and-hold stock picks: one set with a five-year horizon, and....
Is Opko Health Inc. a Buy?
Longtime Opko Health Inc. (NASDAQ: OPK) shareholders have a lot to be upset about. Using about $1.47 billion of its own stock to acquire a big lab service provider a couple years ago was supposed....
Alnylam Pharmaceuticals, Inc.'s Pipeline Progresses, Approval Next
Even though biotech Alnylam Pharmaceuticals (NASDAQ: ALNY) doesn't have any drugs on the market, it had a solid third quarter in terms of pipeline development, with a drug passing its phase 3....
Is Valeant Turning Things Around?
Valeant Pharmaceuticals (NYSE: VRX) is notorious for its drug price gouging scandal a few years ago, an incident that caused the stock to tank and public opinion of the company plummeting to hit....
Ionis Pharmaceuticals Inc. Sets Itself Up for Growth
Ionis Pharmaceuticals' (NASDAQ: IONS) third-quarter earnings were a bit humdrum considering partner Biogen (NASDAQ: BIIB) spilled the beans on sales of Spinraza a few weeks ago when it reported....